Company Overview
Lyka Labs Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical formulations and active pharmaceutical ingredients in India. The company manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-dandruff shampoo, sunscreen, anti-acne, cosmeceutical, anti-oxidant tablets and combination, proton pump inhibitor, nutraceuticals, anti-malarial, anti-bacterial, corticosteroid hormones, cephalosporin, dry powder injection, anti-fungal and bacterial, bone resorption inhibitor, anti-oxidant/liver disease, antibiotic, and lyophilized products. It also offers technical data, such as molecule stability testing data, impurity profile, and BA/BE clinical study data. The company offers its products in various forms, including injections, creams, ointments, foams, gels, and lotions. It also exports its products. The company was incorporated in 1976 and is based in Mumbai, India.
Why Investors Should Care
Revenue has grown at a 13.3% CAGR over the past five years.
Recent Developments
- Mar 2026 Revenue of ₹128.44 Cr (-7.3% YoY); net profit ₹-10.03 Cr.
- Trailing 12 Months Year-on-year growth — revenue -7.3%, earnings -225.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 13.3%, profit CAGR 8.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 13.29% |
| 1 Year: | -7.26% |
Compounded Profit Growth
| 5 Years: | 8.02% |
| 1 Year: | -225.21% |
Stock Price Performance
| 1 Year: | -23.77% |
| 6 Months: | +27.89% |
| 3 Months: | +11.86% |
| 1 Month: | +15.07% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- Golden Cross10d ago
- RSI (14)68.02 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 13.3% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LYKALABS Lyka Labs Limited NSEPHARMA | 78.36 | -31.47 | ₹283.29 Cr | 0.00% | -7.14% | -10.86% | 13.29% | 8.02% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,895.00 | 37.64 | ₹4.55 L Cr | 0.85% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,315.00 | 84.60 | ₹2.47 L Cr | 0.31% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,914.00 | 78.62 | ₹1.87 L Cr | 0.77% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,650.00 | 64.10 | ₹1.24 L Cr | 0.23% | 19.20% | 20.48% | 14.85% | 33.34% |
| 6 | LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA | 688.00 | 237.24 | ₹1.19 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,156.90 | 23.10 | ₹1.16 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 8 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,385.00 | 33.25 | ₹1.12 L Cr | 0.94% | 14.86% | 11.27% | 7.23% | 11.45% |
| 9 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 1,840.00 | 90.86 | ₹99,417.45 Cr | 0.12% | 19.53% | 16.77% | 3.77% | 4.00% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 33.43 Cr | 33.03 Cr | 36.66 Cr | 30.73 Cr | 28.03 Cr |
| Cost of Revenue | 13.08 Cr | 12.74 Cr | 14.88 Cr | 11.55 Cr | 11.03 Cr |
| Gross Profit | 20.34 Cr | 20.29 Cr | 21.78 Cr | 19.17 Cr | 17.00 Cr |
| Operating Expenses | 17.68 Cr | 18.71 Cr | 26.47 Cr | 19.68 Cr | 25.50 Cr |
| Operating Income | 2.67 Cr | 1.57 Cr | -4.69 Cr | -50.59 L | -8.50 Cr |
| EBITDA | 4.90 Cr | 4.32 Cr | -1.45 Cr | 2.81 Cr | -5.84 Cr |
| Interest Expense | 46.81 L | 85.38 L | 78.87 L | 81.64 L | 70.15 L |
| Pretax Income | 3.02 Cr | 1.35 Cr | -4.38 Cr | -16.01 L | -8.59 Cr |
| Tax Provision | 98.94 L | 35.55 L | -1.17 Cr | -89,000 | -51.99 L |
| Net Income | 1.77 Cr | 93.26 L | -3.36 Cr | -3,000 | -7.61 Cr |
| Diluted EPS | 0.49 | 0.25 | -0.94 | 0.00 | -2.13 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 88.34 Cr | 105.13 Cr | 138.50 Cr | 128.44 Cr |
| Cost of Revenue | - | 37.87 Cr | 45.19 Cr | 55.59 Cr | 50.20 Cr |
| Gross Profit | - | 50.47 Cr | 59.94 Cr | 82.90 Cr | 78.25 Cr |
| Operating Expenses | - | 47.72 Cr | 56.98 Cr | 71.74 Cr | 90.36 Cr |
| Operating Income | - | 2.75 Cr | 2.96 Cr | 11.17 Cr | -12.12 Cr |
| EBITDA | - | 12.70 Cr | 16.56 Cr | 20.17 Cr | -15.92 L |
| Interest Expense | - | 11.72 Cr | 4.69 Cr | 2.27 Cr | 3.16 Cr |
| Pretax Income | - | -13.17 Cr | -93.39 L | 11.12 Cr | -11.78 Cr |
| Tax Provision | - | -1.87 L | 1.69 Cr | 3.19 Cr | -1.34 Cr |
| Net Income | - | -13.21 Cr | -2.49 Cr | 8.01 Cr | -10.03 Cr |
| Diluted EPS | - | -4.63 | -0.75 | 2.22 | -2.81 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 151.52 Cr | 156.86 Cr | 176.21 Cr | 174.54 Cr |
| Current Assets | - | 44.20 Cr | 50.65 Cr | 67.43 Cr | 63.28 Cr |
| Cash & Equivalents | - | 2.74 Cr | 25.71 L | 38.93 L | 1.36 Cr |
| Inventory | - | 6.95 Cr | 9.57 Cr | 12.47 Cr | 13.63 Cr |
| Receivables | - | 20.13 Cr | 26.99 Cr | 43.08 Cr | 35.03 Cr |
| Total Liabilities | - | 105.85 Cr | 88.59 Cr | 72.62 Cr | 83.70 Cr |
| Current Liabilities | - | 32.60 Cr | 37.77 Cr | 46.63 Cr | 53.90 Cr |
| Long Term Debt | - | 62.33 Cr | 41.83 Cr | 18.12 Cr | 22.99 Cr |
| Total Debt | - | 73.68 Cr | 57.70 Cr | 38.17 Cr | 48.87 Cr |
| Total Equity | - | 45.44 Cr | 68.15 Cr | 103.55 Cr | 92.39 Cr |
| Shares Outstanding | - | 3.07 Cr | 3.31 Cr | 3.57 Cr | 3.57 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 8.95 Cr | 1.77 Cr | 1.90 Cr | 5.24 Cr |
| Investing Cash Flow | - | 7.35 Cr | -9.49 Cr | -11.80 Cr | -9.41 Cr |
| Financing Cash Flow | - | -21.64 Cr | 1.95 Cr | 5.29 Cr | 4.19 Cr |
| Capital Expenditure | - | -8.19 Cr | -9.23 Cr | -15.65 Cr | -11.13 Cr |
| Free Cash Flow | - | 76.72 L | -7.46 Cr | -13.76 Cr | -5.89 Cr |
| Net Change in Cash | - | -5.34 Cr | -5.76 Cr | -4.60 Cr | 1.51 L |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 57.1% | 57.0% | 59.9% | 60.9% |
| Operating Margin % | - | 3.1% | 2.8% | 8.1% | -9.4% |
| Net Margin % | - | -15.0% | -2.4% | 5.8% | -7.8% |
| ROE % | - | -29.1% | -3.7% | 7.7% | -10.9% |
| ROCE % | - | 2.3% | 2.5% | 8.6% | -10.0% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LYKALABS
Are Lyka Labs Limited's (NSE:LYKALABS) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxNdC1UaHlFQlo4NmgxTmdVWTdwMllEQzVYX29Kc0hBYWFwNEk5SG16aHhQbEIxTy1BUUV2Ri12d2t2aXZ6dkV0MmJBNVI1X0toNE9GRFFlaGdtZldJRC1WbnMzZ1FwMlU1N1h0ZzdsX1F0SThKa0l5Q3haVm05UlVVN1EwZHJjcURJbWF4SU…
Lyka Labs (LYKALABS.NS) Slips 3.34%; Support at ₹68.71 in Focus - Aggressive Growth Picks - vinanet.vn
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxQMmZ6bERRT0JzZkVaTURWWGF6eWlVNk1NMWt3RlhjRzlSZkJ0TE5Iall1aWxHaVIwcURWZ2U0UE9TWHZsSW15eTBZb1lXU0RKNHFIZjBMS2g0TjFFZjNseERDaW9MbDB5MldLaDJoTmk4TlBPUmdpeDFjay0tOFpfR0tnUXM3WkxacUN2dX…
Lyka Labs Stock Prediction 2026: Analyst Target, Forecast and Key Levels - Univest
<a href="https://news.google.com/rss/articles/CBMiZ0FVX3lxTE5rLXVidWxpZTJudk5rUnRJR0FrWkZCVVNnTTJnNGZ2TjFETmRrcWlwVHJPOGJxX2NlM2g3d2o3czkzOE1JVG5LUm9CNlRuZ2pSNHk5MzgwSXR0TTFPQ3JpQkM0SnpWOGs?oc=5" target="_blank">Lyka Labs Stock Prediction 2…
Lyka Labs Q2 2026 Earnings: Revenue Declines 7.26% YoY, Posts Net Loss of ₹2.81 per Share; Stock Gains 4.57% - EBITDA Margin Trends - siam.in
<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxOSklDVllqRV9Lb0RCRDBjZ2k0bFczeDZOWmJpR2EzN01DSElYWmdfSHdDZHk2S2RMZjBKX0JpZURReXl2RFJRd0lvV19qX1d0V1pWclhQaUZ2TG9Udk1vQ1NLRFJVME5xNlc3UHJlTEw5cERnQmZXSEdTX1hPYlphRTItZW9QVU1xdmZDQX…
Lyka Labs posts FY26 net loss of ₹322.88 crore - scanx.trade
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxNTTlMV1lEVzBETF9IMmRmaFIwNzdEZUNpUkdBUWpCMzJMUHdsMkZpZ3BGYkdwVF9aMGw4Q2pPQWo2NTNjQ2dlbTFDY2l4enFPNFQ2Yk9RNVhCdXY1NHRSel9BdzZrYTFaT2c3aS1ya3RFelhQTFQtUUR5eWI3MTVJT20yZW5rNDRQaVZoeX…
Lyka Labs Limited (LYKALABS.NS) Edges Higher Amid Controlled Volume Move - Butterfly Setup - vinanet.vn
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxPbGVIeHljSmJ4X3Z6YTJoazhKNkV2V2hrZVdOQ3RQVjVIbFIwaW5BTWI2QlhRcmZONTlpLS15MDdlQ0llYXFrQTUwNlNVYXRqQkZIMF9leXhkWGFTaVJieUJ2eFBzd05RampGX0xiSDk2UEZBOWpDVjhxbXlFbUIyNVlqWlgzMm12SGE5NV…
LYKALABS — Frequently Asked Questions
What is the current share price of Lyka Labs Limited (LYKALABS)?
As of 2026-09-20 09:43 IST, Lyka Labs Limited (LYKALABS) trades at ₹78.36 on NSE. Its 52-week range is ₹44.95 to ₹102.80.
What is the market capitalisation of LYKALABS?
Lyka Labs Limited (LYKALABS) has a market capitalisation of ₹283.29 Cr on NSE.
What is the P/E ratio of LYKALABS?
LYKALABS trades at a trailing price-to-earnings (P/E) ratio of -31.47. The industry average P/E is 40.02. Its price-to-book (P/B) ratio is 3.21.
What is the return on equity (ROE) of LYKALABS?
LYKALABS has a return on equity (ROE) of -10.86%. Its return on capital employed (ROCE) is -7.14%.
Is LYKALABS a good stock to buy?
This page provides a data-driven analysis of Lyka Labs Limited (LYKALABS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.